Alleviating the storm: ruxolitinib in HLH

Paul La Rosée1

  • 1UNIVERSITÄTSKLINIKUM JENA.

Blood
|April 2, 2016
PubMed

In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).